Skip to main content
. 2022 Aug 24;65:101582. doi: 10.1016/j.molmet.2022.101582

Figure 7.

Figure 7

Ripk3−/− mice are protected from STZ-induced hyperglycemia in vivo. A) Schematic of multiple low dose-streptozotocin (STZ) treatment and blood glucose monitoring. B) Prior to STZ treatment, glucose tolerance was evaluated by intraperitoneal glucose tolerance test (IPGTT) in Ripk3+/+ and Ripk3−/− mice (n = 6/group). C) 10 days after starting STZ treatment, glucose tolerance was evaluated by IPGTT in Ripk3+/+ and Ripk3−/− mice (n = 6/group). D,E) Non-fasting blood glucose was quantified in Ripk3+/+ and Ripk3−/− mice 0, 3, 7, 9 and 14 days after STZ treatment (n = 6/group), and data are displayed over time (D) and at individual time points (E). Data are presented as mean ± SEM and were analyzed by Student's t-test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, p > 0.05; as indicated.